Effect of a high-protein, high-fiber diet plus supplementation with branched-chain amino acids on the nutritional status of patients with cirrhosis.
Study Goal
The researchers aimed to evaluate the safety and efficacy of a high-protein, high-fiber diet combined with BCAA supplementation in improving nutritional status and metabolic markers in patients with cirrhosis.
Results Summary
The study found that the intervention increased muscle mass and reduced fat mass without raising ammonia or glucose levels or causing hepatic encephalopathy, demonstrating safety and some efficacy. No significant adverse effects were reported.
Population
Patients with cirrhosis (72 participants, 37 in the intervention group and 35 in the control group).
Effective Dosage
1.2g/kg protein and 30g fiber daily, plus 110g oral BCAAs daily for the intervention group.
Duration
6 months
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
branched-chain amino acids (BCAAs) | increase | nutritional status | patients with cirrhosis | - | improvement of | #1 |
branched-chain amino acids (BCAAs) | increase | glucose tolerance | patients with cirrhosis | - | improvement of | #2 |
branched-chain amino acids (BCAAs) | decrease | oxidative stress | patients with cirrhosis | - | improvement of | #3 |
branched-chain amino acids (BCAAs) | decrease | inflammatory markers | patients with cirrhosis | - | improvement of | #4 |
a combination of a high-protein, high-fiber diet plus BCAA supplementation | increase | nutritional status | patients with cirrhosis | - | effect of | #5 |
a combination of a high-protein, high-fiber diet plus BCAA supplementation | no change | safety | patients with cirrhosis | - | evaluate the effect of | #6 |
a combination of a high-protein, high-fiber diet plus BCAA supplementation | no change | tolerability | patients with cirrhosis | - | evaluate the effect of | #7 |
BCAA supplement | no change | ammonia levels | patients with cirrhosis | no significant increase | showed no significant increase | #8 |
BCAA supplement | no change | glucose levels | patients with cirrhosis | no significant increase | showed no significant increase | #9 |
BCAA group | increase | muscle mass | patients with cirrhosis | - | increase in | #10 |
BCAA group | decrease | fat mass | patients with cirrhosis | - | decrease in | #11 |
control group | no change | muscle mass | patients with cirrhosis | - | not in | #12 |
control group | no change | fat mass | patients with cirrhosis | - | not in | #13 |
the intervention | no change | Psychometric Hepatic Encephalopathy Score | patients with cirrhosis | no significant changes | no significant changes in | #14 |
the intervention | no change | Critical Flicker Frequency score | patients with cirrhosis | no significant changes | no significant changes in | #15 |
the treatment | no change | hepatic encephalopathy | patients with cirrhosis | no episodes | no episodes of | #16 |
branched-chain amino acids plus a high-fiber, high-protein diet | no change | safety | patients with cirrhosis | - | is a safe intervention | #17 |
branched-chain amino acids plus a high-fiber, high-protein diet | increase | muscle mass | patients with cirrhosis | - | helps increase | #18 |
branched-chain amino acids plus a high-fiber, high-protein diet | no change | levels of ammonia | patients with cirrhosis | - | does not raise | #19 |
branched-chain amino acids plus a high-fiber, high-protein diet | no change | levels of glucose | patients with cirrhosis | - | does not raise | #20 |
branched-chain amino acids plus a high-fiber, high-protein diet | no change | hepatic encephalopathy | patients with cirrhosis | - | nor is it associated with the development of | #21 |
INTRODUCTION AND OBJECTIVES: The potential benefits of branched-chain amino acids (BCAAs) in cirrhosis extend beyond just the improvement of nutritional status. Their effects include improvement of glucose tolerance, oxidative stress, and inflammatory markers, as has been shown in several studies. A dual nutritional approach of a high-protein, high-fiber diet plus BCAAs in cirrhosis could have additional benefits, compared with BCAAs alone. Such an approach has not been explored and therefore the aim of the present study was to evaluate the effect of a combination of a high-protein, high-fiber diet plus BCAA supplementation over a 6-month period of time on the nutritional status of patients with cirrhosis, as well as its safety and tolerability for those same patients. METHODS: An open, randomized clinical trial was conducted. Patients were randomized to one of two groups: the BCAAs+HPHF diet intervention group: a high-protein, high-fiber diet with 1.2g/kg protein and 30g of fiber plus supplementation with oral branched-chain amino acids 110g daily and the HPHF diet control group: a high-protein, high-fiber diet with 1.2g/kg protein and 30g of fiber. The differences between the treatment groups were compared using the unpaired T test and the differences at the end of treatment were compared using the paired T test. RESULTS: A total of 72 patients were included, 37 in the intervention group and 35 in the control group. At the end of the study period, ammonia and glucose levels showed no significant increase in either group, reflecting the safety of the BCAA supplement. Furthermore, muscle and fat mass were evaluated through triceps skinfold thickness and mid-arm muscle circumference measurements. There was an increase in muscle mass and a decrease in fat mass in the BCAA group, but not in the control group. After the intervention, there were no significant changes in the Psychometric Hepatic Encephalopathy Score or the Critical Flicker Frequency score results in either group, and no episodes of hepatic encephalopathy were observed during the treatment period. CONCLUSION: Supplementation with branched-chain amino acids plus a high-fiber, high-protein diet is a safe intervention in patients with cirrhosis. It helps increase muscle mass and does not raise the levels of ammonia or glucose, nor is it associated with the development of hepatic encephalopathy.